Publications 2025

Askeland FB, Bugge VH, Rasmussen AM, Lysén A, Haukås E, Moksnes M, Eilertsen AL, Tsykunova G, Eiken BD, Leknes NM, Rolke J, Stavseth V, Samstad E, Hallstensen RF, Szatkowski D, Hansen AA, Nilsen AS, Slørdahl TS, Abdollahi P, Schjesvold F (2025)
Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospective REMNANT study in transplant-eligible newly diagnosed multiple myeloma
Blood Cancer J, 15 (1), 214
DOI 10.1038/s41408-025-01407-5, PubMed 41429779

Askeland FB, Haukås E, Slørdahl TS, Klostergaard A, Alexandersen T, Lysén A, Abdollahi P, Nielsen LK, Hermansen E, Schjesvold F (2025)
Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial
Lancet Haematol, 12 (2), e120-e127
DOI 10.1016/S2352-3026(24)00347-8, PubMed 39909655

Slørdahl TS, Askeland FB, Hanssen MSS, Hov H, Sundt-Hansen SM, Lindahl S, Vethe NT, Hjorth-Hansen H, Fenstad MH, Waage A, Hjertner Ø, Schjesvold F, Sundan A (2025)
Combined Proteasome and Autophagy Inhibition in Relapsed/Refractory Multiple Myeloma-A Phase I Trial of Hydroxychloroquine, Carfilzomib, and Dexamethasone
EJHaem, 6 (1), e1091
DOI 10.1002/jha2.1091, PubMed 39866949

Publications 2024

Askeland FB, Frøen HM, Bolstad N, Thorsby PM, Schjesvold F, Wammer ACP, Følling I, Tjønnfjord GE (2024)
Monoclonal Insulin Autoimmune Syndrome Successfully Treated With Plasma Cell Directed Therapy
Clin Lymphoma Myeloma Leuk, 25 (3), e127-e130
DOI 10.1016/j.clml.2024.10.005, PubMed 39500643